Tian Sa, Qin Defang, Ye Yixuan, Yang Huawei, Chen Shuguang, Liu Tao, Hu Luming, Li Huiming, Niu Qian, Zhang Xingzhan
Department of Intensive Care Unit, Guangdong Provincial Hospital of Chinese Medicine, Zhuhai, China.
Evid Based Complement Alternat Med. 2021 Oct 25;2021:6879278. doi: 10.1155/2021/6879278. eCollection 2021.
To systematically collate, appraise, and synthesize the current evidence on the Xuebijing injection (XBJI) for sepsis.
Eight databases were searched for systematic reviews (SRs) or meta-analyses (MAs) on XBJI for sepsis. Assessing the Methodological Quality of Systematic Reviews-2 (AMSTAR-2), Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA), and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methods were used to assess the methodological quality, reporting quality, and evidence quality of the enrolled studies, respectively.
Out of the 13 studies that were included, all studies were rated critically low quality based on AMSTAR-2 results. Based on the results obtained from PRISMA, all studies were reported to be over 80%, while the GRADE system yielded three outcome measures rated high-quality, 16 were of moderate quality, and the rest were of low or critically low quality.
The combination of XBJI and Western medicine (WM) showed significant synergy for the treatment of sepsis compared to WM alone. However, this conclusion should be treated with caution since the quality of the SRs/MAs providing the evidence was relatively low.
系统整理、评估和综合当前关于血必净注射液（XBJI）治疗脓毒症的证据。
检索八个数据库，查找关于XBJI治疗脓毒症的系统评价（SRs）或荟萃分析（MAs）。分别采用系统评价方法学质量评估-2（AMSTAR-2）、系统评价和荟萃分析优先报告项目（PRISMA）以及推荐分级、评估、制定与评价（GRADE）方法，评估纳入研究的方法学质量、报告质量和证据质量。
纳入的13项研究中，根据AMSTAR-2结果，所有研究的质量等级均为极低。根据PRISMA结果，所有研究的报告率均超过80%，而GRADE系统得出三项结局指标为高质量，16项为中等质量，其余为低质量或极低质量。
与单纯西医治疗相比，XBJI联合西医治疗脓毒症显示出显著的协同作用。然而，由于提供证据的SRs/MAs质量相对较低，该结论应谨慎对待。
